Raymond James Reinstates Market Perform on Vertex Pharmaceuticals
Portfolio Pulse from Benzinga Newsdesk
Raymond James analyst Danielle Brill has reinstated a Market Perform rating on Vertex Pharmaceuticals (NASDAQ:VRTX).

October 10, 2024 | 12:58 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Raymond James has reinstated a Market Perform rating on Vertex Pharmaceuticals, indicating a neutral stance on the stock's performance.
The Market Perform rating suggests that the analyst expects the stock to perform in line with the market. This neutral rating may not significantly impact the stock price in the short term, as it does not indicate a strong buy or sell signal.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100